共 201 条
[1]
MacDonald MR(2008)Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme Eur Heart J 29 1377-1385
[2]
Petrie MC(2008)Diabetes, left ventricular systolic dysfunction, and chronic heart failure Eur Heart J 29 1224-1240
[3]
Varyani F(2003)Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study Diabetes Care 26 855-860
[4]
Ostergren J(2013)Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 1317-1326
[5]
Michelson EL(2015)Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial Lancet 385 2067-2076
[6]
Young JB(2018)Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial JACC Heart Fail 6 8-17
[7]
MacDonald MR(2015)Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N Engl J Med 373 232-242
[8]
Petrie MC(2019)Effect of linagliptin vs. placebo on major cardiovascular events in adults with type 2 Diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial JAMA 321 69-2128
[9]
Hawkins NM(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-657
[10]
Petrie JR(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 377 644-357